Evaluation of intratumoral response heterogeneity in metastatic colorectal cancer and Its impact on patient overall survival: findings from 10,551 patients in the ARCAD database

Ou, Fang-Shu, Ahn, Daniel H., Dixon, Jesse G., Grothey, Axel, Lou, Yiyue, Kasi, Pashtoon M., Hubbard, Joleen M., Van Cutsem, Eric, Saltz, Leonard B., Schmoll, Hans-Joachim, Goldberg, Richard M., Venook, Alan P., Hoff, Paulo, Douillard, Jean-Yves, Hecht, J. Randolph, Hurwitz, Herbert, Punt, Cornelis J. A., Koopman, Miriam, Bokemeyer, Carsten, Fuchs, Charles S., Diaz-Rubio, Eduardo, Tebbutt, Niall C., Cremolini, Chiara, Kabbinavar, Fairooz F., Bekaii-Saab, Tanios, Chibaudel, Benoist, Yoshino, Takayuki, Zalcberg, John, Adams, Richard A. ORCID: https://orcid.org/0000-0003-3915-7243, de Gramont, Aimery and Shi, Qian 2023. Evaluation of intratumoral response heterogeneity in metastatic colorectal cancer and Its impact on patient overall survival: findings from 10,551 patients in the ARCAD database. Cancers 15 (16) , 4117. 10.3390/cancers15164117

PDF - Published Version Available under License Creative Commons Attribution. Download (5MB)

Abstract

Metastatic colorectal cancer (mCRC) is a heterogeneous disease that can evoke discordant responses to therapy among different lesions in individual patients. The Response Evaluation Criteria in Solid Tumors (RECIST) criteria do not take into consideration response heterogeneity. We explored and developed lesion-based measurement response criteria to evaluate their prognostic effect on overall survival (OS). Patients and Methods: Patients enrolled in 17 first-line clinical trials, who had mCRC with ≥ 2 lesions at baseline, and a restaging scan by 12 weeks were included. For each patient, lesions were categorized as a progressing lesion (PL: > 20% increase in the longest diameter (LD)), responding lesion (RL: > 30% decrease in LD), or stable lesion (SL: neither PL nor RL) based on the 12-week scan. Lesion-based response criteria were defined for each patient as follows: PL only, SL only, RL only, and varied responses (mixture of RL, SL, and PL). Lesion-based response criteria and OS were correlated using stratified multivariable Cox models. The concordance between OS and classifications was measured using the C statistic. Results: Among 10,551 patients with mCRC from 17 first-line studies, varied responses were noted in 51.6% of patients, among whom, 3.3% had RL/PL at 12 weeks. Among patients with RL/SL, 52% had stable disease (SD) by RECIST 1.1, and they had a longer OS (median OS (mOS) = 19.9 months) than those with SL only (mOS = 16.8 months, HR (95% CI) = 0.81 (0.76, 0.85), p < 0.001), although a shorter OS than those with RL only (mOS = 25.8 months, HR (95% CI) = 1.42 (1.32, 1.53), p < 0.001). Among patients with SL/PL, 74% had SD by RECIST 1.1, and they had a longer OS (mOS = 9.0 months) than those with PL only (mOS = 8.0 months, HR (95% CI) = 0.75 (0.57, 0.98), p = 0.040), yet a shorter OS than those with SL only (mOS = 16.8 months, HR (95% CI) = 1.98 (1.80, 2.18), p < 0.001). These associations were consistent across treatment regimen subgroups. The lesion-based response criteria showed slightly higher concordance than RECIST 1.1, although it was not statistically significant. Conclusion: Varied responses at first restaging are common among patients receiving first-line therapy for mCRC. Our lesion-based measurement criteria allowed for better mortality discrimination, which could potentially be informative for treatment decision-making and influence patient outcomes.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Medicine Centre for Trials Research (CNTRR)
Publisher:	MDPI
ISSN:	2072-6694
Date of First Compliant Deposit:	30 August 2023
Date of Acceptance:	9 August 2023
Last Modified:	31 Aug 2023 01:41
URI:	https://orca.cardiff.ac.uk/id/eprint/162025

Actions (repository staff only)

Edit Item